IL149532A0 - Treatment of subnormal bone mineral density - Google Patents

Treatment of subnormal bone mineral density

Info

Publication number
IL149532A0
IL149532A0 IL14953200A IL14953200A IL149532A0 IL 149532 A0 IL149532 A0 IL 149532A0 IL 14953200 A IL14953200 A IL 14953200A IL 14953200 A IL14953200 A IL 14953200A IL 149532 A0 IL149532 A0 IL 149532A0
Authority
IL
Israel
Prior art keywords
treatment
bone mineral
mineral density
individual
agent
Prior art date
Application number
IL14953200A
Other languages
English (en)
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of IL149532A0 publication Critical patent/IL149532A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14953200A 1999-11-12 2000-11-13 Treatment of subnormal bone mineral density IL149532A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16508999P 1999-11-12 1999-11-12
US09/710,729 US6605591B1 (en) 1999-11-12 2000-11-10 Treatment of subnormal bone mineral density
PCT/US2000/030131 WO2001035975A2 (en) 1999-11-12 2000-11-13 Treatment of subnormal bone mineral density

Publications (1)

Publication Number Publication Date
IL149532A0 true IL149532A0 (en) 2002-11-10

Family

ID=26861107

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14953200A IL149532A0 (en) 1999-11-12 2000-11-13 Treatment of subnormal bone mineral density

Country Status (16)

Country Link
US (3) US6605591B1 (pt)
EP (1) EP1231983B1 (pt)
JP (1) JP2003514026A (pt)
KR (1) KR20020063183A (pt)
CN (1) CN1411386A (pt)
AT (1) ATE326265T1 (pt)
AU (1) AU784160B2 (pt)
BR (1) BR0015534A (pt)
CA (1) CA2390431A1 (pt)
DE (1) DE60028074D1 (pt)
IL (1) IL149532A0 (pt)
MX (1) MXPA02004776A (pt)
NO (1) NO20022246L (pt)
NZ (1) NZ518791A (pt)
RU (1) RU2002115815A (pt)
WO (1) WO2001035975A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
DE60233485D1 (de) 2001-05-25 2009-10-08 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
US7840247B2 (en) * 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) * 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
EP1605824A2 (en) 2003-03-25 2005-12-21 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
US20080058613A1 (en) * 2003-09-19 2008-03-06 Imaging Therapeutics, Inc. Method and System for Providing Fracture/No Fracture Classification
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
PT2460515T (pt) * 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
AU2009253839B2 (en) * 2008-06-03 2011-07-28 John Ray Biffin A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU743121B2 (en) 1996-11-25 2002-01-17 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
KR20000071039A (ko) * 1997-02-13 2000-11-25 비숍 찰스 더블유. 비타민 ｄ 화합물의 표적화된 치료학적 전달
CN100544726C (zh) 1999-03-18 2009-09-30 基因实验室技术公司 Dhea制剂及方法
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density

Also Published As

Publication number Publication date
WO2001035975A2 (en) 2001-05-25
ATE326265T1 (de) 2006-06-15
RU2002115815A (ru) 2004-02-27
KR20020063183A (ko) 2002-08-01
US20050113301A1 (en) 2005-05-26
WO2001035975A3 (en) 2001-12-27
DE60028074D1 (de) 2006-06-22
US7612034B2 (en) 2009-11-03
EP1231983B1 (en) 2006-05-17
US20030158159A1 (en) 2003-08-21
CA2390431A1 (en) 2001-05-25
AU1580201A (en) 2001-05-30
EP1231983A2 (en) 2002-08-21
CN1411386A (zh) 2003-04-16
NZ518791A (en) 2004-03-26
JP2003514026A (ja) 2003-04-15
NO20022246L (no) 2002-07-03
BR0015534A (pt) 2002-07-02
AU784160B2 (en) 2006-02-16
MXPA02004776A (es) 2003-01-28
US6854468B2 (en) 2005-02-15
US6605591B1 (en) 2003-08-12
NO20022246D0 (no) 2002-05-10

Similar Documents

Publication Publication Date Title
IL149532A0 (en) Treatment of subnormal bone mineral density
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
BG105534A (en) 5ht1 means and method for the treatment of migraine
HUP0102951A3 (en) Apparatus for treatment of meniere's disease and similar conditions
EP1005345A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC ASTHMA AND OTHER CONDITIONS USING DESCARBOETHOXYLORATADINE
WO2001010375A3 (en) Inhibition of action potentials
AU5729098A (en) Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
AU1833699A (en) Device and method for treating parkinson's disease
ZA98721B (en) Use of dehydroepiandrosterone to treat primary adrenal insufficiency and addison's disease.
EP1011644A4 (en) METHOD AND APPARATUS FOR THE TREATMENT OF PARKINSON'S DISEASE
NZ292940A (en) Use of an aromatase inhibitor and/or an androgen receptor anatonist as a cosmetic agent to reduce hair loss
AUPP674898A0 (en) A method of treatment
AU4370900A (en) Treatment of systemic lupus erythematosis
HU9700073D0 (en) Heterocycle-condensed morphinoid derivatives
GB2331301C (en) Galanin
WO2003049667A3 (en) The method of treating cancer
AU4946699A (en) Method of treating meniere's disease and corresponding apparatus
HK1019702A1 (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders
PL349514A1 (en) Agents and method for treating keratinous fibres
IL119354A0 (en) Method and device for treatment of the brainstem
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
EP1009433A4 (en) THERAPEUTIC COMPOSITION AND TREATMENT METHOD
EP1188431A3 (de) Verfahren zum Dauerwellen von menschlichen Haaren
GB9709769D0 (en) Composition and method of treating skin disorders
GB9609927D0 (en) Composition and method of treating skin disorders